## ACHN (ATCC® CRL-1611™)

Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma

| GENERAL INFORMATION     | CHARACTERISTICS | CULTURE METHOD                                   | SPECIFICATIONS          | HISTORY | DOCUMENTATION | SHARE | EMAIL | PRINT |
|-------------------------|-----------------|--|-------------------------|---------|---------------|-------|-------|-------|
| Permits and Restriction | S View Per      | mlts   |                         |         |               |       |       |       |
| Organism                | Homo sapien     | s, human   | 1 - 1/2                 | vij es  |               |       |       |       |
| Tissue                  | kidney; derive  | d from metastatic site:                          | pleural effusion        |         |               |       |       |       |
| Product Format          | frozen          |  |                         |         |               |       |       |       |
| Morphology              | epithelial      |  |                         |         |               |       |       |       |
| Culture Properties      | adherent        |  |                         |         |               |       |       |       |
| Blosafety Level         | 1               |  |                         |         |               |       |       |       |
|                         |                 | sification is based on <u>U</u>                  |                         |         |               |       |       |       |
|                         |                 | is the responsibility of to                      |                         |         |               |       |       |       |
|                         | country.        | comply with biosafoty r                          | əguləvons tor their ow. | 7       |               |       |       |       |
| Disease                 | renal cell ader | nocarcinoma                                      |                         |         |               |       |       |       |
| Age                     | 22 years        | -  |                         |         |               |       |       |       |
| Gender                  | male            |  |                         |         |               |       |       |       |
| Ethnicity               | Caucasian       |  |                         |         |               |       |       |       |
| Applications            |                 | of use for antipreliferat<br>nterferon inducers. | ive studies using hum   | an      |               |       |       |       |
| Storage Conditions      | liquid nitrogen | vapor temperature                                |                         |         |               |       |       |       |

https://www.atcc.org/Products/All/CRL-1611.aspx?&p=1&rel=general information#general information#general



# ACHN (ATCC® CRL-1611™)


| GENERAL INFORMATION | CHARACTERISTICS  | CULTURE METHOD  | SPECIFICATIONS   | HISTORY                            | DOCUMENTATION | SHARE | EMAIL | PRIN |
|---------------------|--|---|--|------------------------------------|---------------|-------|-------|------|
| Derivation          | malignant pl<br>widely metas<br>Cells were s<br>10% FBS, th<br>Cells were th<br>4 weeks, pal<br>original cells | cell line was initiated in Neural effusion of a 22-ye.  Static renal adenocarcing eeded directly to culture an maintained and passion inoculated subcutant pable, locally invasive to (ACHN) and those recognowth-inhibited by hum  | ar-old Caucasian male<br>ma (autopsy confirme<br>flasks in Eagle's MEM<br>aged 150 days in flask<br>cously into nude mice,<br>mors were noted. Bot<br>vered from nude mous | e with od). I with cs. After h the |               |       |       |      |
| Clinical Data       | 22 years<br>Caucasian<br>male  | Commission of the state of the |  |                                    |               |       |       |      |
| Tumorigenic         | Yes  |   | 2 and 2  | ·-                                 |               |       |       |      |
| Effects             | •  | mice<br>eloped within 21 days at<br>oculated subcutaneously   |  | in                                 |               |       |       |      |
| Comments            | Growth is inh  | aibited by human interfer   | on [Hogan, T. F., perso  | onal                               |               |       |       |      |






## ACHN (ATCC® CRL-1611™)

| SENERAL INFORMATION  | CHARACTERISTICS                              | CULTURE METHOD  | SPECIFICATIONS   | HISTORY                 | DOCUMENTATION | SHARE | EMAIL | PRIN |
|----------------------|--|---|--|-------------------------|---------------|-------|-------|------|
| Complete Growth Medi | Minimum Es<br>complete gro                   | adium for this cell line is<br>sential Medium, Catalog<br>owth medium, add the fo<br>n: fetal bovine serum to   | No. 30-2003. To make   | the the                 |               |       |       |      |
| Subculturing         | amount of di<br>vessels of ot                |   | ed proportionally for c  |                         |               |       |       |      |
|                      |  | and discard culture med   |  |                         |               |       |       |      |
|                      | No NASSESSED UN                              | nse the cell layer with 0.2<br>lution to remove all trace<br>hibitor.   | STREET, STREET |                         |               |       |       |      |
|                      | observe<br>disperse<br>Note: To<br>shaking t | to 3.0 mL of Trypsin-EDT cells under an inverted n d (usually within 5 to 15 avoid clumping do not a the flask while waiting for difficult to detach may be . | nicroscope until cell lay<br>minutes).<br>gitate the cells by hittir<br>the cells to detach. C   | yer is<br>ng or<br>ells |               |       |       |      |
|                      |  | o 8.0 mL of complete greently pipetting.  |  |                         |               |       |       |      |
|                      | <ol><li>Add appr<br/>vessels.</li></ol>      | <ol><li>Add appropriate aliquots of the cell suspension to new culture<br/>vessels.</li></ol>   |  |                         |               |       |       |      |
|                      | 6. Incubate                                  | 6. Incubate cultures at 37°C.   |  |                         |               |       |       |      |
|                      | recommende                                   | on Ratio: A subcultivation deewal: 2 to 3 times per w   |  |                         |               |       |       |      |
| Cryopreservation     |  | um: Complete growth m<br>perature: liquid nitrogen  |  | 5%                      |               |       |       |      |
| Culture Conditions   | Atmosphere<br>Temperature                    | : air, 95%; carbon dioxid   | e (CO <sub>2</sub> ), 5%   |                         |               |       |       |      |



# ACHN (ATCC® CRL-1611™)


| SEVERAL INFORMATION | CHARACTERISTICS   | CULTURE METHOD | SPECIFICATIONS   | HISTORY           | DOCUMENTATION | SHARE | EMAIL | PRI |
|---------------------|---|----------------|------------------|-------------------|---------------|-------|-------|-----|
| STR Profile         | Amelogenin:<br>CSF1PO: 11<br>D13S317: 12<br>D16S539: 12<br>D5S818: 12<br>D7S820: 9,1<br>THO1: 8<br>TPOX: 8,11<br>vWA: 16,17 | 2<br>2,13      |                  |                   |               |       |       |     |
| Isoenzymes          | G6PD, B   |                | Lamanon - Amanon | 5,6 0.11141111111 |               |       |       |     |





# ACHN (ATCC® CRL-1611™)

| SENERAL INFORMATION | CHARACTERISTICS  | CULTURE METHOD           | SPECIFICATIONS       | HISTORY | DOCUMENTATION | SHARE | EMAIL | PRII |  |
|---------------------|--|--------------------------|----------------------|---------|---------------|-------|-------|------|--|
| Name of Depositor   | TF Hogan   |                          |                      |         |               |       |       |      |  |
| Deposited As        | Homo sapie   | ns                       |                      |         |               |       |       |      |  |
| Year of Origin      | November,  | 1979                     |                      |         |               |       |       |      |  |
| References          | Tumors deve  | eloped within 21 days at | 100% frequency (5/5) | In      |               |       |       |      |  |
|                     | nude mice inoculated subcutaneously with 10(7) cells             |                          |                      |         |               |       |       |      |  |
|                     | The ACHN of  |                          |                      |         |               |       |       |      |  |
|                     | malignant pleural effusion of a 22-year-old Caucasian male with  |                          |                      |         |               |       |       |      |  |
|                     | widely meta:   |                          |                      |         |               |       |       |      |  |
|                     | Cells were seeded directly to culture flasks in Eagle's MEM with |                          |                      |         |               |       |       |      |  |
|                     | 10% FBS, then maintained and passaged 150 days in flasks.        |                          |                      |         |               |       |       |      |  |
|                     | Cells were then inoculated subcutaneously into nude mice. After  |                          |                      |         |               |       |       |      |  |
|                     | 4 weeks, palpable, locally invasive tumors were noted. Both the  |                          |                      |         |               |       |       |      |  |
|                     | original cells (ACHN) and those recovered from nude mouse        |                          |                      |         |               |       |       |      |  |
|                     | tumors were growth-inhibited by human interferons.               |                          |                      |         |               |       |       |      |  |
|                     | Kochevar J. Blockage of autonomous growth of ACHN cells by       |                          |                      |         |               |       |       |      |  |
|                     | anti-renal cell carcinoma monoclonal antibody 5F4. Cencer Res.   |                          |                      |         |               |       |       |      |  |
|                     | 20: 2968-2972, 1990. PubMed: 2334900                             |                          |                      |         |               |       |       |      |  |





# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

